Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
For gene knockdown study, IPEC-J2 cells were infected with shLacz cloned adenovirus (AdshLacz) or shGPX4 cloned adenovirus (AdshGPX4) or shSELS cloned adenovirus (AdshSELS) at MOI of 50 for 48 h
This precaution helps prevent any unforeseen interactions and ensures safe use of the injection alongside other treatments
Underwriters are also getting better at detecting GLP-1 use through: Prescription databases Medical records requests Follow-up health questionnaires What This Means for Your Clients If currently on GLP-1 medications: Expect questions about medication use and duration Be prepared for potentially higher rates despite current health improvements Consider timing of application if they've been stable on medication for an extended period If recently stopped GLP-1 medications: Underwriters may view recent discontinuation as a risk factor Weight regain could further complicate the application process Medical follow-up showing sustained health improvements may help If planning to start GLP-1 medications: Understand that future applications may be affected by medication use Industry Trends to Watch Some forward-thinking insurance companies are exploring partnerships with GLP-1 providers to improve medication adherence
The company projects that its weight loss-offerings, which also include oral medications, will bring in $100 million in revenue by the end of 2025
Most studies are small and include semaglutide used as monotherapy or combination therapy (with an insulin SGLT2i) with completion dates ranging from 2024 through 2029
US$ 29.70
US$ 23.65
US$ 29.59
US$ 29.16
US$ 28.39
